ErbB receptors and cancer
Z Wang - ErbB receptor signaling: methods and protocols, 2017 - Springer
The ErbB receptor family, also known as the EGF receptor family or type I receptor family,
includes the epidermal growth factor (EGF) receptor (EGFR) or ErbB1/Her1, ErbB2/Her2 …
includes the epidermal growth factor (EGF) receptor (EGFR) or ErbB1/Her1, ErbB2/Her2 …
Oral complications of targeted cancer therapies: a narrative literature review
AL Watters, JB Epstein, M Agulnik - Oral oncology, 2011 - Elsevier
The aim of the present study was to investigate the available literature regarding the oral
side effects or adverse events associated with targeted cancer therapy. Common oral …
side effects or adverse events associated with targeted cancer therapy. Common oral …
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study
Q Zhou, CR Xu, Y Cheng, YP Liu, GY Chen, JW Cui… - Cancer cell, 2021 - cell.com
Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth
factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung …
factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung …
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma
Recent advances in the treatment of pulmonary adenocarcinoma have increased the need
for accurate typing of non–small cell carcinomas. Immunohistochemistry for thyroid …
for accurate typing of non–small cell carcinomas. Immunohistochemistry for thyroid …
Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation
C Stahlhut, FJ Slack - Cell cycle, 2015 - Taylor & Francis
Lung cancer represents the leading cause of cancer-related deaths in men and women
worldwide. Targeted therapeutics, including the epidermal growth factor receptor (EGFR) …
worldwide. Targeted therapeutics, including the epidermal growth factor receptor (EGFR) …
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
MS Cragg, C Harris, A Strasser, CL Scott - Nature Reviews Cancer, 2009 - nature.com
Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for
cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted …
cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted …
[HTML][HTML] Recent advances in anti-angiogenic therapy of cancer
Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is
a highly promising therapeutic approach. Thus, for over last couple of decades, there has …
a highly promising therapeutic approach. Thus, for over last couple of decades, there has …
[HTML][HTML] Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
C Masuda, M Yanagisawa… - International …, 2017 - spandidos-publications.com
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
[HTML][HTML] Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
Non-small-cell lung cancer (NSCLC) is a leading cause of malignancy-related mortality in
the Western world. Despite advances in early detection and standard treatment, NSCLC is …
the Western world. Despite advances in early detection and standard treatment, NSCLC is …
Peptide G-protein-coupled receptors and ErbB receptor tyrosine kinases in cancer
Simple Summary Cancer growth is regulated by receptor tyrosine kinases (RTKs) and G-
protein-coupled receptors (GPCRs). The epidermal growth factor receptor (EGFR) is an RTK …
protein-coupled receptors (GPCRs). The epidermal growth factor receptor (EGFR) is an RTK …